Wearable Sweat Sensors: Background and Current Trends

Sweat‐related physiology research has been well established over the years. However, it has only been around ten years that sweat‐based sensing devices started to be explored. With the recent advancements in wearable activity and physiology monitoring devices, sweat was investigated for its contents similar to blood and corresponding wearable devices were studied intensively. This article provides a thorough review on sweating mechanisms, sweat sensing devices, and electronic technologies for sweat sensor implementations. Potential future directions and recommendations based on current research trends were provided in each section. This review aims to offer a unique perspective from both physiology and engineering point‐of‐view to draw a complete landscape of the sweat sensing research

Targeting cytokine signaling checkpoint CIS activates NK cells to protect from tumor initiation and metastasis

The cytokine-induced SH2-containing protein CIS belongs to the suppressor of cytokine signaling (SOCS) protein family. Here, we show the critical role of CIS in suppressing natural killer (NK) cell control of tumor initiation and metastasis. Cish-deficient mice were highly resistant to methylcholanthrene-induced sarcoma formation and protected from lung metastasis of B16F10 melanoma and RM-1 prostate carcinoma cells. In contrast, the growth of primary subcutaneous tumors, including those expressing the foreign antigen OVA, was unchanged in Cish-deficient mice. The combination of Cish deficiency and relevant targeted and immuno-therapies such as combined BRAF and MEK inhibitors, immune checkpoint blockade antibodies, IL-2 and type I interferon revealed further improved control of metastasis. The data clearly indicate that targeting CIS promotes NK cell antitumor functions and CIS holds great promise as a novel target in NK cell immunotherapy

Whole blood stabilization for the microfluidic isolation and molecular characterization of circulating tumor cells

Precise rare-cell technologies require the blood to be processed immediately or be stabilized with fixatives. Such restrictions limit the translation of circulating tumor cell (CTC)-based liquid biopsy assays that provide accurate molecular data in guiding clinical decisions. Here we describe a method to preserve whole blood in its minimally altered state by combining hypothermic preservation with targeted strategies that counter cooling-induced platelet activation. Using this method, whole blood preserved for up to 72 h can be readily processed for microfluidic sorting without compromising CTC yield and viability. The tumor cells retain high-quality intact RNA suitable for single-cell RT-qPCR as well as RNA-Seq, enabling the reliable detection of cancer-specific transcripts including the androgen-receptor splice variant 7 in a cohort of prostate cancer patients with an overall concordance of 92% between fresh and preserved blood. This work will serve as a springboard for the dissemination of diverse blood-based diagnostics